Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Prolia therapy for postmenopausal women with osteoporosis

June 3, 2010

Novo Nordisk to soon launch Victoza in Japan

June 3, 2010

FDA accepts Qnexa NDA for obesity for review

June 2, 2010

Genfit receives approval for two IT-Diab trials in France

June 2, 2010

Phase II trial of BCX-4208 with or without allopurinol initiated in gout

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA committee recommends approval of tesamorelin

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

NICE issues recommendation for somatropin products, including Omnitrope

May 31, 2010

Galderma claims new melanocortin MC4 receptor antagonists

May 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...